Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM

Amrita Krishnan • 23 Nov 2020
ASH 2020
Multiple Myeloma Antibodies Teclistamab

Amrita Krishnan, MD, City of Hope National Medical Center, Duarte, CA discusses the results of a relapsed/refractory multiple myeloma (MM) trial (NCT03145181) of teclistamab, a bispecific BCMA-CD3 antibody that activates T-cell killing of BCMA-expressing MM cells. Subcutaneous (SC) and intravenous administration was investigated in the process of establishing a recommended Phase II dose. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Amrita Krishnan

0:49
Management of patients with penta-class refractory myeloma
Amrita Krishnan • 11 Dec 2023
1:01
Considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
Amrita Krishnan • 11 Dec 2023
0:50
Dose modifications of talquetamab to manage AEs in patients with multiple myeloma
Amrita Krishnan • 11 Dec 2023
1:15
How BCMA targeting bispecific antibodies may impact the subsequent use of CAR-T therapy in myeloma
Amrita Krishnan • 29 Sep 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals